Tempus AI wins FDA approval for tumor-only solid tumor assay
Tempus AI said it received FDA approval for a tumor-only solid-tumor assay and set an ADLT price of $4,500 effective Jan. 1, projecting $80—100M in added revenue; shares fell Friday after a post-approval rally tied to reimbursement optimism.